Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart vs IVIg in Multifocal Motor Neuropathy
NCT06742190Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in multifocal motor neuropathy (MMN) (3 arms), sponsored by argenx. Primary endpoint: Change from baseline in grip strength (4-week average) in the most affected hand at 24 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NCT06742190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742190.